A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: whether a specific approach is justified to tackle the challenges?

ABSTRACT:

Objectives

Discounting the cost and effect for health intervention is a controversial topic over the last two decades. In particular, the cost-effectiveness of gene therapies is especially sensitive to the discount rate because of the substantial delay between the upfront cost incurred and long-lasing clinical benefits received. This study aims to investigate the influence of employing alternative discount rates on the incremental cost-effectiveness ratio (ICER) of gene therapies.

Methods

A systematic review was conducted to include health economic evaluations of gene therapies that were published until April 2023.

Results

Sensitivity or scenario analysis indicated that discount rate represented one of the most influential factors for the ICERs of gene therapies. Disc

SUBMITTER: Qiu T 

PROVIDER: S-EPMC11569993 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature